Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme

Michael L. Gruber, Jon Glass, Haroon F Choudhri, Anita Nirenberg

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The authors evaluated the efficacy of neoadjuvant carboplatin chemotherapy before external-beam irradiation in patients who had histologically proven glioblastoma multiforme. Twenty-five patients were treated with carboplatin, 600 mg/m2, intravenously once every 4 weeks for a total of 4 planned cycles. External-beam irradiation (60 Gy involved field) was planned after carboplatin. Of 15 patients who had residual tumor assessable for response, seven had stable disease, six had partial responses, one had a complete response, and one had progressive disease. Two of the patients who had partial responses progressed before radiotherapy. Of 10 who had gross total resections, two progressed after 3 to 4 cycles. The median time to tumor progression was 8.4 months. Median survival was 19.2 months. Myelotoxicity and other side effects of treatment were modest. Carboplatin chemotherapy after biopsy or resection of glioblastoma multiforme before irradiation is feasible. These results warrant further clinical investigation of the role that carboplatin chemotherapy may have in the treatment of patients who have newly diagnosed glioblastoma multiforme.

Original languageEnglish (US)
Pages (from-to)338-340
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume21
Issue number4
DOIs
StatePublished - Aug 1 1998

Fingerprint

Carboplatin
Glioblastoma
Drug Therapy
Residual Neoplasm
Radiotherapy
Biopsy
Survival
Therapeutics
Neoplasms

Keywords

  • Carboplatin
  • Drug therapy
  • Glioblastoma multiforme
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme. / Gruber, Michael L.; Glass, Jon; Choudhri, Haroon F; Nirenberg, Anita.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 21, No. 4, 01.08.1998, p. 338-340.

Research output: Contribution to journalArticle

Gruber, Michael L. ; Glass, Jon ; Choudhri, Haroon F ; Nirenberg, Anita. / Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1998 ; Vol. 21, No. 4. pp. 338-340.
@article{fd4d336d0018444b9092cc0f3116ebf4,
title = "Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme",
abstract = "The authors evaluated the efficacy of neoadjuvant carboplatin chemotherapy before external-beam irradiation in patients who had histologically proven glioblastoma multiforme. Twenty-five patients were treated with carboplatin, 600 mg/m2, intravenously once every 4 weeks for a total of 4 planned cycles. External-beam irradiation (60 Gy involved field) was planned after carboplatin. Of 15 patients who had residual tumor assessable for response, seven had stable disease, six had partial responses, one had a complete response, and one had progressive disease. Two of the patients who had partial responses progressed before radiotherapy. Of 10 who had gross total resections, two progressed after 3 to 4 cycles. The median time to tumor progression was 8.4 months. Median survival was 19.2 months. Myelotoxicity and other side effects of treatment were modest. Carboplatin chemotherapy after biopsy or resection of glioblastoma multiforme before irradiation is feasible. These results warrant further clinical investigation of the role that carboplatin chemotherapy may have in the treatment of patients who have newly diagnosed glioblastoma multiforme.",
keywords = "Carboplatin, Drug therapy, Glioblastoma multiforme, Radiotherapy",
author = "Gruber, {Michael L.} and Jon Glass and Choudhri, {Haroon F} and Anita Nirenberg",
year = "1998",
month = "8",
day = "1",
doi = "10.1097/00000421-199808000-00004",
language = "English (US)",
volume = "21",
pages = "338--340",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme

AU - Gruber, Michael L.

AU - Glass, Jon

AU - Choudhri, Haroon F

AU - Nirenberg, Anita

PY - 1998/8/1

Y1 - 1998/8/1

N2 - The authors evaluated the efficacy of neoadjuvant carboplatin chemotherapy before external-beam irradiation in patients who had histologically proven glioblastoma multiforme. Twenty-five patients were treated with carboplatin, 600 mg/m2, intravenously once every 4 weeks for a total of 4 planned cycles. External-beam irradiation (60 Gy involved field) was planned after carboplatin. Of 15 patients who had residual tumor assessable for response, seven had stable disease, six had partial responses, one had a complete response, and one had progressive disease. Two of the patients who had partial responses progressed before radiotherapy. Of 10 who had gross total resections, two progressed after 3 to 4 cycles. The median time to tumor progression was 8.4 months. Median survival was 19.2 months. Myelotoxicity and other side effects of treatment were modest. Carboplatin chemotherapy after biopsy or resection of glioblastoma multiforme before irradiation is feasible. These results warrant further clinical investigation of the role that carboplatin chemotherapy may have in the treatment of patients who have newly diagnosed glioblastoma multiforme.

AB - The authors evaluated the efficacy of neoadjuvant carboplatin chemotherapy before external-beam irradiation in patients who had histologically proven glioblastoma multiforme. Twenty-five patients were treated with carboplatin, 600 mg/m2, intravenously once every 4 weeks for a total of 4 planned cycles. External-beam irradiation (60 Gy involved field) was planned after carboplatin. Of 15 patients who had residual tumor assessable for response, seven had stable disease, six had partial responses, one had a complete response, and one had progressive disease. Two of the patients who had partial responses progressed before radiotherapy. Of 10 who had gross total resections, two progressed after 3 to 4 cycles. The median time to tumor progression was 8.4 months. Median survival was 19.2 months. Myelotoxicity and other side effects of treatment were modest. Carboplatin chemotherapy after biopsy or resection of glioblastoma multiforme before irradiation is feasible. These results warrant further clinical investigation of the role that carboplatin chemotherapy may have in the treatment of patients who have newly diagnosed glioblastoma multiforme.

KW - Carboplatin

KW - Drug therapy

KW - Glioblastoma multiforme

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0031818560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031818560&partnerID=8YFLogxK

U2 - 10.1097/00000421-199808000-00004

DO - 10.1097/00000421-199808000-00004

M3 - Article

VL - 21

SP - 338

EP - 340

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -